Quadrivio player in the Italian Private Equity market, has 60 professionals and more than 1 billion euros under management announces, alongside the first fund TTVenture the new fund TTVenture Two with a capitalization objective of 100 million euros.
Continuing with the experience gained from the first fund, TTVenture Two will invest in start-ups and highly innovative technology with a specific focus on the areas of Life Sciences, MedTech, New Materials and Cleantech.
On March 26, 2014, the Board of Directors of Quadrivio appointed Elizabeth Marie Robinson as the new “Director of Investments” in the area of Venture Capital and Valentina Bocca as CIO (Chief Investment Officer) of the fund TTVenture.
Mrs. Robinson, 57, earned her Ph.D. in Biotechnology at the Massachusetts Institute of Technology. She has over 20 years of experience in the Venture Capital business and Angel Investing at both national and international levels. Today she is one of the leading experts in the field of Life Sciences with a successful track record.
Elizabeth Robinson is President of Nicox Research Institute and co-founder of Nicox SA.
With the arrival of the new manager, along with other new professionals, the TTVenture team will significantly strengthen its expertise and international network.
The investment committee of the new fund will also include: Börje Ekholm, 30 years of experience in Private Equity and Venture Capital, President and CEO of Investor AB, Chairman of NASDAQ OMX, Chairman of the KTH Royal Institute of Technology; Mario Ferrario, 30 years of experience in Private Equity and Venture Capital, Co-Founder and President of Schroeder Italy MCF Capital Partners; Galeazzo Scarampi, 30 years of experience in Private Equity. Former member of the Management Board and Investment Manager for Investor AB (Asia) and IFI International/Exor30; Pierluigi Zappacosta, 30 years of entrepreneurial and investment experience, Founder and President of Logitech Lighthouse Venture.
The inclusion of these new resources will allow for greater internationalization and a higher valuation of the target companies, with the objective of speeding up the investment and disinvestment process.
The first TTVenture fund invested in: AIM, Bionsil, Biouniversa, Bluegreen, Cogisen, CryptoLab, Directa Plus, D-Orbit, Eucardia, Glomeria Therapeutics, IpadLab, M31, MilkyWay, Pilegrowth Tech, Personal Factory, San Severino, Sem+, TTSeed, TTAdvisor